Increased ribavirin dose in HIV/HCV co-infected patients leads to increased serum concentration of ribavirin by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Increased ribavirin dose in HIV/HCV co-infected patients leads to 
increased serum concentration of ribavirin
F Almasi*, G Spiridon, V Jullien, JF Merritet, P Sogni and D Salmon
Address: Cochin Hospital, Paris, France
* Corresponding author    
Purpose of the study
Ribavirin in combination with pegylated interfreon alpha
2a is the standard treatment for chronic HCV hepatitis.
Body weight and/or HCV genotype are factors which
determine ribavirin dosage. Ribavirin's side-effects, espe-
cially anemia, are negatively related to its serum concen-
tration and its efficacy is positively related to serum
concentration, respectively.
Methods
Ribavirin's serum concentration was measured in 20 HIV/
HCV co-infected patients who were eligible for HCV treat-
ment 4 weeks after treatment commenced. A serum con-
centration of 2.2 microgram/ml is considered as
therapeutic level. Dose of ribavirin was increased as 200
milligram daily (not more than 1,200 mg/day) in patients
whose ribavirin serum concentration was less than 2.2
microgram/ml. Hemoglobin levels measured at first day
of treatment and 3 months later.
Summary of results
Mean ribavirin serum concentration in 20 patients was
1.96 microgram/ml (R: 0.8–5.2). Seven of 20 (35%) of
patients had a serum concentration of ribavirin more than
2.2 microgram/ml (mean: 3) while 13 of 20 patients
(65%) had not achieved therapeutic level (mean: 1.4).
Dose of ribavirin was increased in nine of 13. Nearly all
(8/9) found an increase in serum concentration of ribavi-
rin. 50% of them had achieved the therapeutic level (2.2
microgram/ml) while four patients, in spite of increased
serum concentration of ribavirin, did not reach therapeu-
tic level. Totally, 11 of 20 (55%) reached 2.2 while nine of
20 (45%) less than 2.2. Decreased hemoglobin level was
observed nearly in all patients. Mean: 2 g/dl (range: -0.1–
5.6). In patients who reached therapeutic level of ribavirin
decreased Hb level was more important (mean: 2.3 g/dl)
than patients who did not achieved 2.2 microgram/ml
(mean: 1.6 g/dl). We did not find any correlation between
ribavirin serum concentration and early virologic
response nor sustained virologic response.
Conclusion
Increased dose of ribavirin leads to increase serum con-
centration of ribavirin. Along with increased serum con-
centration of ribavirin, the rate of decreased hemoglobin
level increases.
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